Nektar Therapeutics NKTR Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's pre-tax income?
- Nektar Therapeutics (NKTR) reported pre-tax income of -$43.09M in Q1 2026.
- How has Nektar Therapeutics's pre-tax income changed year-over-year?
- Nektar Therapeutics's pre-tax income increased by 7.1% year-over-year, from -$46.37M to -$43.09M.
- What is the long-term trend for Nektar Therapeutics's pre-tax income?
- Over 4 years (2021 to 2025), Nektar Therapeutics's pre-tax income has grown at a -26.2% compound annual growth rate (CAGR), from -$523.28M to -$155.49M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.